Nielsen Thøger, Kristensen Anne Flou, Pedersen Shona, Christiansen Gunna, Kristensen Søren Risom
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
J Extracell Vesicles. 2018 Mar 26;7(1):1454777. doi: 10.1080/20013078.2018.1454777. eCollection 2018.
Tissue factor (TF) is the main initiator of coagulation and procoagulant phospholipids (PPL) are key components in promoting coagulation activity in blood. Both TF and PPL may be presented on the surface of extracellular vesicles (EVs), thus contributing to their procoagulant activity. These EVs may constitute a substantial part of pathological hypercoagulability that is responsible for triggering a higher risk of thrombosis in certain patients. The aim of this study was to describe a model system for the isolation of EVs required for investigating their effect on coagulation. Differential ultracentrifugation (DUC) with and without a single washing step was used to isolate and evaluate the procoagulant capacity of EVs from healthy volunteers through analysis of thrombin generation and PPL activity. Ultracentrifugation at 20,000 × and 100,000 × resulted in pellets containing larger vesicles and smaller vesicles, respectively. Isolation yield of particle concentration was assessed by nanoparticle tracking analysis. Immunoelectron microscopy and western blotting revealed vesicles positive for the commonly used EV-marker CD9. Plasma proteins and lipoproteins were co-isolated with the EVs; however, application of a washing step clearly diminished the amount of contaminants. The isolated EVs were capable of enhancing thrombin generation, mainly due to PPL predominantly present in pellets from 20,000 × g centrifugation, and correlated with the activity measured by a PPL activity assay. Thus, DUC was proficient for the isolation of EVs with minimal contamination from plasma proteins and lipoproteins, and the setup can be used to study EV-associated procoagulant activity. This may be useful in determining the procoagulant activity of EVs in patients at potentially increased risk of developing thrombosis, e.g. cancer patients. : TF: Tissue factor; PL: Phospholipids; EVs: Extracellular vesicles; FXa: Activated coagulation factor X; TGA: Thrombin generation assay; PPL: Procoagulant phospholipids; DUC: Differential ultracentrifugation; NTA: Nanoparticle tracking analysis; TEM: Transmission electron microscopy; SPP: Standard pool plasma; CTI: Corn trypsin inhibitor; 20K: 20,000 × ; 100K: 100,000 × ; FVIII: Coagulation factor VIII.
组织因子(TF)是凝血的主要启动因子,促凝磷脂(PPL)是促进血液中凝血活性的关键成分。TF和PPL均可呈现在细胞外囊泡(EVs)表面,从而促成其促凝活性。这些EVs可能构成病理性高凝状态的重要部分,而病理性高凝状态会引发某些患者更高的血栓形成风险。本研究的目的是描述一种用于分离EVs的模型系统,以研究其对凝血的影响。采用有或无单次洗涤步骤的差速超速离心法(DUC),通过分析凝血酶生成和PPL活性,从健康志愿者中分离并评估EVs的促凝能力。20,000×和100,000×超速离心分别得到含有较大囊泡和较小囊泡的沉淀。通过纳米颗粒跟踪分析评估颗粒浓度的分离产率。免疫电子显微镜和蛋白质印迹显示囊泡对常用的EV标志物CD9呈阳性。血浆蛋白和脂蛋白与EVs共同分离;然而,采用洗涤步骤明显减少了污染物的量。分离出的EVs能够增强凝血酶生成,这主要归因于主要存在于20,000×g离心沉淀中的PPL,并且与通过PPL活性测定法测得的活性相关。因此,DUC能够有效地从血浆蛋白和脂蛋白中分离出污染最小的EVs,该方法可用于研究与EVs相关的促凝活性。这对于确定血栓形成风险可能增加的患者(如癌症患者)中EVs的促凝活性可能是有用的。:TF:组织因子;PL:磷脂;EVs:细胞外囊泡;FXa:活化的凝血因子X;TGA:凝血酶生成测定;PPL:促凝磷脂;DUC:差速超速离心;NTA:纳米颗粒跟踪分析;TEM:透射电子显微镜;SPP:标准混合血浆;CTI:玉米胰蛋白酶抑制剂;20K:20,000×;100K:100,000×;FVIII:凝血因子VIII。